Compare COHN & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COHN | SCNX |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Other Pharmaceuticals |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 16.2M |
| IPO Year | 2003 | 2019 |
| Metric | COHN | SCNX |
|---|---|---|
| Price | $10.12 | $0.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 22.1K | ★ 303.8K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ 5537.50 | N/A |
| EPS | ★ 1.36 | N/A |
| Revenue | ★ $275,564,000.00 | $3,831,778.00 |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | $7.43 | ★ N/A |
| Revenue Growth | ★ 246.19 | 30.72 |
| 52 Week Low | $9.19 | $0.24 |
| 52 Week High | $32.60 | $2.60 |
| Indicator | COHN | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.55 |
| Support Level | N/A | $0.30 |
| Resistance Level | N/A | $0.43 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 37.33 |
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.